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Abstract
Background: Trials in rare diseases have many challenges, among which are the need to set up multiple sites in
different countries to achieve recruitment targets and the divergent landscape of clinical trial regulations in those
countries. Over the past years, there have been initiatives to facilitate the process of international study set-up, but
the fruits of these deliberations require time to be operationally in place. FOR-DMD (Finding the Optimum Steroid
Regimen for Duchenne Muscular Dystrophy) is an academic-led clinical trial which aims to find the optimum steroid
regimen for Duchenne muscular dystrophy, funded by the National Institutes of Health (NIH) for 5 years (July 2010 to
June 2015), anticipating that all sites (40 across the USA, Canada, the UK, Germany and Italy) would be open to recruitment
from July 2011. However, study start-up was significantly delayed and recruitment did not start until January 2013.
Method: The FOR-DMD study is used as an example to identify systematic problems in the set-up of international,
multi-centre clinical trials. The full timeline of the FOR-DMD study, from funding approval to site activation, was collated
and reviewed. Systematic issues were identified and grouped into (1) study set-up, e.g. drug procurement; (2) country
set-up, e.g. competent authority applications; and (3) site set-up, e.g. contracts, to identify the main causes of delay and
suggest areas where anticipatory action could overcome these obstacles in future studies.
(Continued on next page)
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Results: Time from the first contact to site activation across countries ranged from 6 to 24 months. Reasons of delay were
universal (sponsor agreement, drug procurement, budgetary constraints), country specific (complexity and diversity of
regulatory processes, indemnity requirements) and site specific (contracting and approvals). The main identified obstacles
included (1) issues related to drug supply, (2) NIH requirements regarding contracting with non-US sites, (3) differing
regulatory requirements in the five participating countries, (4) lack of national harmonisation with contracting and the
requirement to negotiate terms and contract individually with each site and (5) diversity of languages needed for study
materials. Additionally, as with many academic-led studies, the FOR-DMD study did not have access to the infrastructure
and expertise that a contracted research organisation could provide, organisations often employed in pharmaceuticalsponsored studies. This delay impacted recruitment, challenged the clinical relevance of the study outcomes and potentially
delayed the delivery of the best treatment to patients.
Conclusion: Based on the FOR-DMD experience, and as an interim solution, we have devised a checklist of steps to not
only anticipate and minimise delays in academic international trial initiation but also identify obstacles that will require a
concerted effort on the part of many stakeholders to mitigate.
Keywords: Clinical trial, Academic-led clinical trial, Clinical trial regulations, Duchenne muscular dystrophy, Rare disease,

Background
The research and patient communities are united in the
opinion that rare diseases (defined in the USA as diseases
affecting fewer than 200,000 people at any given time and
in the European Union (EU) as diseases affecting fewer
than 5 people in 10,000 [1]) require new and better therapies [2]. A tangible sign of the commitment to this cause
is that an international consortium of funders has been set
up to ensure that financial resources will be in place to
develop and deliver 200 new therapies for rare diseases by
2020 [2]. Drug development programmes in rare diseases
have many challenges [3], some of which differ from those
facing researchers working on common diseases: the lack
of clinical and research-savvy experts, which results in difficulties in setting up and running studies at inexperienced
sites and the scarcity of patients, which means that largescale studies will always require the set-up of multiple
centres in different countries to achieve recruitment
targets for proof-of-efficacy clinical trials.
Academic-led studies have the additional challenge of
budgetary and capacity constraints [4]. As a result, it is
difficult for academic-led studies to access contracted
research organisations (CROs). These organisations have
an international infrastructure of regulatory specialists
and are delegated the responsibility of gaining regulatory
and site approvals, avoiding inexperienced investigators
and their study teams having to learn and navigate the
processes themselves, therefore aiding multi-centre trial
set-up [5]. In both rare and common diseases, clinical
trials with multiple sites in different countries pose many
challenges due to the diversity, both between and within
nations, with reference to care standards [5], laws, regulations and guidelines governing clinical trials [5–7]. The
incompatibility between countries’ policies when setting
up international studies and the consequent bureaucratic
delays has been highlighted with specific reference to

North America and Europe [7] and National Institutes
of Health (NIH)-funded studies [5, 6, 8].
However, international, multi-centre studies provide
an added value by promoting global standards of care
and expansion of the market for new treatments; this is
particularly apparent in rare diseases due to the limited
number of experts [4, 9, 10]. In addition, academic-led
studies hold their own value [7, 11], often focussing on
ideas to improve patient care that may not have as much
financial gain to the pharmaceutical industry, like drug
repurposing or the method in which a drug is administered, as in the case of FOR-DMD (Finding the Optimum
Steroid Regimen for Duchenne Muscular Dystrophy).
In recognition of the importance and challenge of international studies, there have recently been initiatives to
standardise and harmonise the regulatory aspects of
clinical research worldwide. This has been occurring in
both our area of expertise: Duchenne muscular dystrophy,
a rare neuromuscular disease affecting mainly boys, and in
more general regulatory fields. The EU has awarded funding to disease-specific networks, such as TREAT-NMD, a
neuromuscular network to provide the infrastructures to
ensure efficient delivery of new therapies to patients [12],
and generic networks, such as ECRIN (European Clinical
Research Infrastructure Network) [13] and EATRIS
(European Infrastructure for Translational Medicine) [14],
in order to support trial development. Moreover, in 2004,
the Voluntary Harmonisation Procedure [15] was
developed in the EU to streamline the review process for
competent authority applications for multi-centre clinical
trials, recognising this challenge. However, as the name
suggests, there is no legal obligation for EU countries to
take part in this process, which has had limited application
so far [16]. The release of the updated EU clinical trial regulations [17], due for implementation in 2017, aims to further streamline the regulatory system in all EU countries
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in a binding legislative act, to ease the burden for multicentre, international studies [18].
In the USA, efforts to reduce bureaucratic delays have
been introduced with NeuroNEXT (Network for Excellence in Neuroscience Clinical Trials), an organisation set
up by the National Institute of Neurological Disorders and
Stroke to increase the efficiency of clinical trials and
expand the capability to promptly deliver new therapies
for neurological disorders to patients [19]. NeuroNEXT
has created a centralised system, which ensures a single
human subject/ethics review, contracting process, coordination centre, data management and statistics centre for
multi-centre studies [20]. In addition, the proposed
changes to the Common Rule (Federal Policy for the
Protection of Human Subjects) [21] set out to streamline
approval processes for multi-centre clinical trials in order
to avoid the widely recognised, unnecessary regulatory
reviews and lack of efficiency in the current system [22,
23]. However, both the NeuroNEXT initiative and the
proposed changes to the Common Rule focus on US
multi-centre trials and do not apply outside the USA.
Harmonisation between the USA and EU countries in
terms of regulatory requirements and law has not been
achieved yet, and, therefore, setting up clinical trials across
the EU and USA remains challenging [6, 7, 24]. The landscape is complex, and failure to resolve the issues around
regulatory and bureaucratic deferrals in international
studies continues to delay the progress of therapy development. In the rare disease field, this will result in a failure
to achieve the targets set by the International Rare Diseases Research Consortium (IRDiRC) [2].

Methods
The FOR-DMD (Finding the Optimum Steroid Regimen
for Duchenne Muscular Dystrophy, ClinicalTrials.gov identifier NCT01603407) study is a multi-centre international
study, funded by the NIH, addressing the current equipoise
in the use of corticosteroids in Duchenne muscular dystrophy (DMD) [25]. Despite evidence from both randomised trials and cohort studies that corticosteroids are of
benefit in DMD [26–28], clinicians continue to be very
divided in prescribing corticosteroids in DMD. There are
up to 27 different type and dosage regimens currently in
routine use, and in some centres, corticosteroids are not
prescribed at all [29]. The FOR-DMD study aims to recruit
300 DMD subjects across 40 sites in five different countries
(USA, Canada, UK, Germany and Italy) to receive one of
the three most commonly prescribed corticosteroid regimens in DMD (daily prednisone, daily deflazacort and
intermittent prednisone, 10 days on/10 days off) with the
aim to overcome the inconsistencies in corticosteroid prescription. The duration of the study was 3 to 5 years, anticipating that the recruitment target would have been reached
in 2 years from study site opening.
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The study received funding from the NIH in July 2010
with the understanding that the study would take 6 years:
1 year for study set-up, 2 years for recruitment with each
participant being treated and followed up in a blinded
manner for 3–5 years depending on when enrolled.
Study preparation focussed primarily on contract negotiations between the Sponsor, University of Rochester
(recipient of the NIH award) and Newcastle Upon Tyne
NHS Hospitals Foundation Trust (NUTH) in the UK
(the Sponsor’s Legal Representative in the European
Economic Area (EEA) and on drug manufacture. The intent was for recruitment to begin in July 2011; however,
the first study sites were not opened for recruitment
until January 2013.
Here, we review the process of the FOR-DMD study
from funding approval to site activation with the aim to
identify the main causes of delay and suggest a checklist
of areas of improvements that could predict and potentially overcome these obstacles in future studies.
Although the work on the FOR-DMD study development
started much earlier (in 2004), for the purposes of this
review, we analysed the set-up process only from the time
when funding was approved (July 2010) through to initiation of the 40 sites in the five countries that were originally
selected to take part.
We analysed the process to set up the collaboration
between the Sponsor and the EU Legal Representative, to
obtain final study approval in the five countries and in
each participating site (Fig. 1). Systematic issues were
identified and grouped into (1) study set-up: activities (e.g.
drug procurement) that needed to be done before any site
in the trial could be opened to recruitment; (2) country
set-up: tasks (e.g. competent authority applications) that
needed to be done within a given country; and (3) site setup: activities that needed to be done to finalise individual
site approvals.

Results
Study set-up challenges
Protocol reviews

During the set-up of the FOR-DMD study, the protocol
was reviewed 43 times by the NIH and the competent
authorities and ethics committees in the five countries
involved. In fact, very few modifications were necessary
after each single review, but this iterative process delayed
the finalisation of the study protocol and the subsequent
activities (e.g. submission to regulatory authorities).
Budgetary restrictions

The limited resources and budget available for the FORDMD study contributed to the delay in study start-up. At
the onset, it precluded the possibility to finance CROs to
support the regulatory process in the different countries.
Additionally, the limited finances allowed no room for site

Crow et al. Trials (2018) 19:291

Page 4 of 9

Fig. 1 FOR-DMD timeline. Average set-up times for the FOR-DMD study

budget negotiation and difficulties with translation of
regulatory and study documents (e.g. contracts, questionnaires). Furthermore, there was no contingency for the
costs resulting from delays (e.g. additional drug manufacture campaigns to replace expired study drug) or the
fluctuation of exchange rates and inflation.
Sponsor agreement

FOR-DMD is funded by a US sponsor (NIH) but is also
conducted outside the USA. Therefore, according to the
EU Clinical Trials Directive, which is the guidance that
governs clinical trials in Europe, it is required to have a
Legal Representative in the European Economic Area to act
as an agent for the sponsor in the event of legal actions.
This role was delegated to NUTH in the UK. Clarification
of roles and responsibilities between the ‘Sponsor’ and
‘Sponsor’s Legal Representative’ required lengthy repeated
discussion between the University of Rochester and NUTH
before resolution could be achieved. Involvement of legal
representatives for both parties to address risk aversion
caused delays in excess of 6 months.
Drug procurement

Procurement of the study drug was an additional cumbersome process that created unanticipated delays. Because
the UK has much lower infrastructure overheads than the
USA, drug supply was coordinated by the EU Legal Representative in the UK. Subsequently, drug procurement fell
under EU procurement law, which requires a tendering
process: a 30-day advertisement and a 40-day window for
the invitation to tender to be returned. Because young

study subjects were expected to have difficulty swallowing
large, over-encapsulated standard stock tablets, studyspecific manufactured tablets were required. This change
in the drug preparation, coupled with the need for data on
the manufacturing process and on stability testing to feed
into the Investigational Medicinal Product (IMP) dossier
(including the Investigator Brochure) (required for all
competent authority applications), stalled study initiation.
Country set-up challenges
Insurance

Per the EU Clinical Trials Directive, insurance or indemnity
to cover the liability of the investigator and sponsor must
be secured before commencement of a clinical trial. In the
USA and Canada, there are no government mandates for
clinical trial liability insurance. Rather, liability falls under
the global insurance policy held by each institution. In the
EU, insurance and indemnity requirements vary from
country to country with no international consistency. For
example, Italy requires that each study subject is covered
up to €1M, while Germany specifies €500,000. Because
insurance requirements were not anticipated, additional
time had to be allocated for negotiation around budget.
Furthermore, Italy’s financial coverage mandates were
modified during the time period between FOR-DMD study
planning and trial inception, the compliance with which
resulted in even further expense and delay.
Translation

An agreement was reached prior study set-up that participating sites were able to accept study documents in English.
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However, this agreement was set up with the site investigators and did not take into account the requirements of the
site’s legal and financial departments. As a result, expenses
for translation of study documents into the recruiting countries’ local languages were not fully budgeted in the original
grant (i.e. to allow for country- and site-specific modifications), and therefore, final translation of documents was
not completed until additional funds were secured from
Patient Advocacy Groups (i.e. Italian Telethon). Also, each
country had different requirements in terms of document
sets that required translation, which was unclear even to
the leading site in each country. Until translations were
finalised, submission of the study to regulatory authorities
in each country was delayed.
Lack of regulatory harmonisation

In all countries involved in FOR-DMD, there were different regulatory approval processes (including competent
authority, ethical and site approvals); this was even the
case in countries within the EU. A schematic of clinical
trial regulatory approval processes in each participating
country is provided in Fig. 2. Each country imposed a
distinct and not necessarily overlapping time frame for
progress through the regulatory pathway with different
conditions at each step. This was compounded by drug
manufacturing changes at a ‘study set-up’ level, which
meant that essential documents, such as Investigator
Brochures, were not available in a timely manner.
Site set-up challenges
Communication

Not using CROs in each country meant that all communications with sites were managed centrally by the study
team. Communication in different languages and across
multiple time zones was challenging and oftentimes confusing and possibly caused delay in individual site activation.
NIH requirements

The US government has specific requirements for studies
funded by their institutions, in this case the NIH. These
apply not only to entities in the USA but also to non-USbased recipients. All site staff must have proof of Human
Subjects Research Training/Good Clinical Practice (GCP).
In some EU countries, however, specific GCP certification
is not mandatory for clinical staff (i.e. physiotherapists);
instead, the clinician only needs to have the relevant training for the tasks that they routinely carry out as part of
their job description, regardless of whether that job will be
contributing to delivering research. Obtaining GCP compliance from staff at sites, otherwise not subject to this
regulation, proved difficult. Moreover, once an individual
agreed to obtain the GCP training, they were faced with
the challenge of how to accomplish the task. NIH offers a
free online course that meets the GCP requirements;
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however, the course is only offered in English. Although it
was a requirement that site Principal Investigators were
competent with documents and correspondence in English,
language was an issue for other site staff who do not routinely interact in English for clinical and non-clinical duties.
For trials funded by US government organisations (such
as the NIH), any site conducting human subjects research
must obtain a Federal Wide Assurance (FWA) number,
which ensures site compliance with protecting the rights
and welfare of human subjects. Additionally, each site
must obtain a DUNS (Data Universal Numbering System)
number. This number is a unique identifier maintained in
a database for entities doing business with (or funded by)
the US government. While both of these procedures may
be completed online, the systems are often unfamiliar to
non-US entities. Registrations of this nature typically must
be completed by institution administrators (rather than
study staff) who may not be fluent in English. Furthermore, compliance may be an issue in countries where
these pieces of information are not typically mandated
(particularly obtaining a DUNS number).
Site contracts (subaward agreements) with non-US
entities were further slowed by site registration with the
System for Award Management (SAM), which combines
federal procurement systems with a central contractor
registry. SAM registration is required for US entities
receiving federal funds (whether directly or as a subaward)
but is not currently mandated by the NIH for non-US
institutions. However, it is not unusual for the primary
award recipient (in this case, the University of Rochester)
to require SAM registration for its subaward recipients.
SAM registration is completed online, but the submission
form is complicated and cumbersome for entities in the
EU, which are completely unfamiliar with the format and
some of the US-specific terminology. Language barriers,
time zone differences and hold times for telephone support (often in excess of 1 h) add to the sites’ burden for
completing this task.
Site contracts

A UK model Clinical Trial Agreement was used in
conjunction with the typical subaward agreement used
in the USA, in order to address both EU and US regulations and so that the foreign sites would have a document to review with which (we anticipated) they were
already somewhat familiar. However, legal language for
clinical trial contracting still caused misunderstanding
or conflict with country-specific terminology even
within EU sites. This specifically applied to terms like
‘conflict of interest’, ‘intellectual property’ and ‘court of
jurisdiction’. Negotiations with Italian sites, for
example, continued over several months to determine
which court (whether based in the USA or in Italy)
would be used in case of subaward agreement dispute
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Fig. 2 Regulatory approval process. Schematics for approvals in the USA, Canada, Germany, Italy and the UK

(court of jurisdiction). Each time the subaward agreement was reviewed/edited, this added additional delay
and cost (e.g. for translation).

Discussion
The experience of the FOR-DMD study is not unique.
Whether in common or rare disease, there have been a
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number of similar experiences published by investigators
working on multi-centre, publically funded clinical trials
[5–8, 10, 11]. A lack of regulatory harmonisation inside the
EU and between the EU and USA has been reported by
many as having the most negative impact in these types of
trials, at the centre of this criticism being the EU Clinical
Trials Directive [6, 7, 10, 11]. Funder requirements can add
a huge additional administrative burden to investigators,
particularly when setting up numerous sites globally [5, 6,
8]. There are also differing institutional policies across sites
that impact timelines for contracting [5, 8, 10]. Moreover,
language barriers exacerbate the ability to overcome these
problems quickly [6, 8]. These issues are having a negative
impact on multi-centre research.
With this in mind, the current situation appears to be
incongruous when considering the ambitious goals set by
IRIDIRC for rare diseases [2]. Experienced investigators are
struggling to produce results, owing to the fact that the
international, multi-centre clinical trials vital to collect
enough data for a study to be viable are extremely difficult
to set up.

Initiatives to harmonise approvals

Over the past years, there have been some initiatives to
facilitate the process of investigator-led, international
study set-up [12–14, 19], but the fruits of these deliberations are not always immediately obvious or operationally
in place. In Europe, the highly criticised [18] EU Clinical
Trials Directive [30] is due to be replaced by the EU
Clinical Trial Regulation, which promises to ease the
regulatory burden in the EU countries and provide more
harmonisation also for studies that are led and/or funded
by the USA [18]. However, these regulations will not be
released until 2017, implementation will be gradual, and
the document has already been criticised as insufficiently
detailed to improve the current situation [31].
To avoid the delays caused through inconsistencies in
interpretation of the current EU Clinical Trials Directive,
academic networks such as EATRIS and ECRIN have
made attempts to provide information about the different regulations and provide international co-ordination
[13, 14]. As their application to rare disease to date has
been limited, it remains to be seen if their involvement
can help to obviate some of the issues encountered in
the FOR-DMD trial.
Within the neurology and neuromuscular field in the
USA, networks such as NeuroNEXT and CINRG (Cooperative International Neuromuscular Research Group) have
tried to harmonise and centrally coordinate the issues of
shared contracts and master agreements [20, 32]. However,
incentives to use such common formats remain limited and
will require concerted action from regulatory and other
national authorities.

Fig. 3 Checklist. A checklist to aid implementing an international,
multi-centre, academic-led clinical trial
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Although it is widely accepted that harmonisation is
needed, and initiatives are being implemented, it will take
time for them to be adopted and for improvements to
become apparent. This is time that we cannot afford to
waste in the development of treatments for rare disease;
therefore, interim measures must be made available.
An interim aid

Using the experiences of setting up the FOR-DMD
study, we have developed a checklist of common obstacles and required anticipatory actions (Fig. 3 along with
Additional file 1). Shown to be a simple but effective
tool within a clinical setting and beyond, the use of a
checklist to aid sequencing a complex task has been
shown to improve outcomes in clinical practice [33, 34].
This approach therefore not only aims to speed up the
set-up of academic-led international clinical trials but
also allows investigators to gain a realistic expectation
of timelines. The checklist does not aim to change the
complex regulatory approval process as it stands, but
rather to serve as an interim navigational tool for
investigators wanting to develop new treatments using
multi-centre clinical trials. We believe that the realistic
planning of a clinical trial taking into account the
points illustrated in this review will anticipate obstacles
and will finally result in an improvement in delivery of
clinical trials.

Conclusion
Our analysis of the set-up of the FOR-DMD study
demonstrates that the international regulatory approval
system is complex and there is evidence to show that
this causes lengthy delays for clinical trial set-up. Given
the high need for treatment in rare disease, there is a
need for harmonisation. However, more recently, study
set-up initiatives have been implemented to facilitate
international investigator-led trials, but time is required
to operationalise and assess their impact. Perhaps
incongruously, there is an extensive push by national
and international research organisations to develop new
treatments in rare disease, which the current complex
system is making difficult to achieve; this is demonstrated by the experience of the FOR-DMD study. It
will be up to the national regulatory bodies overseeing
research to see if the challenges we have highlighted
here can really be addressed. It is not possible for
individual groups to change such a complex approval
system, but we have used our experience to suggest a
checklist and an interim solution, which could represent a useful tool to support academic-led research and
will go some way to start bridging the gap between the
need to research in rare disease and the regulatory
disharmony.
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Additional file
Additional file 1: Checklist supplementary information. Supplementary
information to implementing an international, multi-centre, academic-led
clinical trial: checklist. (DOCX 115 kb)

Abbreviations
CINRG: Cooperative International Neuromuscular Research Group;
CRO: Contracted research organisations; DMD: Duchenne muscular
dystrophy; DUNS: Data Universal Numbering System; EATRIS: European
Infrastructure for Translational Medicine; ECRIN: European Clinical Research
Infrastructure Network; EEA: European Economic Area; EU: European Union;
FOR-DMD: Finding the Optimum Steroid Regimen for Duchenne Muscular
Dystrophy; FWA: Federal Wide Assurance; GCP: Good Clinical Practice;
IMP: Investigational Medicinal Product; IRDiRC: International Rare Diseases
Research Consortium; NeuroNEXT: Network for Excellence in Neuroscience
Clinical Trials; NIH: National Institutes of Health; NUTH: Newcastle Upon Tyne
NHS Hospitals Foundation Trust; SAM: System for Award Management;
TREAT-NMD: Translational Research in Europe - Assessment and Treatment of
Neuromuscular Diseases
Acknowledgements
FOR-DMD is sponsored by the National Institutes of Health (study number
U01NS061799) and has also received funding from Telethon Italy, the
Muscular Dystrophy Association (MDA) and Parent Project Muscular
Dystrophy (PPMD). We acknowledge the patient and family organisations
including Action Duchenne, Muscular Dystrophy UK, Muscular Dystrophy
Canada and Benni & Co/Parent Project for their promotion of the study.
The FOR-DMD Steering Committee and the study site investigators are
members of the Muscle Study Group. Michela Guglieri and Kate Bushby
are part of the Medical Research Council (UK) and TREAT-NMD who also
supported the study. Finally, we are very grateful to the boys participating
in the study, as well as their families, all site investigators, research nurses,
physiotherapists and study coordinators for their commitment and continuous
contribution to the study.
Funding
The National Institutes of Health (study number U01NS061799). Telethon
Italy. Muscular Dystrophy Association (MDA). Parent Project Muscular
Dystrophy (PPMD).
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
RAC and KAH researched the data and wrote the article. MPM, RT, WBM,
BEH, EM, JW, JK, WMK, ME, MWB, TW, DH, HL, VS, EC, PBS, SS, AMC, AYM, LM,
RJB, IH, HR, KMF, NLK, JKM, LM, BTD, MH, US, EW, TM, CMM, GV, RJB, RSF,
MW, HJM, IH, EP, WBB, JFH, MT and CC reviewed and edited the manuscript.
RCG, KB and MG made substantial contribution to the content. All authors
read and approved the final manuscript.
Ethics approval and consent to participate
This manuscript does not directly contain human data; however, its topic
is a clinical trial in which all patients were appropriately consented and
ethics approval was granted from the University of Rochester Research
Subjects Review Board (RSRB# 38795/#44449), as well as from the local
ethics committees at each recruiting site.
Consent for publication
There was no specific informed consent sought for this publication because it
does not contain any patient data. However, as part of the FOR-DMD clinical
trial, full informed consent was obtained before any patient started the study.
Competing interests
The authors declare that they have no competing interests.

Crow et al. Trials (2018) 19:291

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1
John Walton Muscular Dystrophy Research Centre, Institute of Genetic
Medicine, Newcastle University, Newcastle upon Tyne NE1 3BZ, UK.
2
University of Rochester Medical Center, Rochester, NY, USA. 3Newcastle
University, Newcastle upon Tyne, UK. 4University Medical Center, Freiburg,
Germany. 5National Institutes of Health, Bethesda, MD, USA. 6UCLA, Los
Angeles, CA, USA. 7Alder Hey Children’s Hospital, Liverpool, UK. 8Leeds
Teaching Hospitals, Leeds, UK. 9GOSH, UCL, London, UK. 10Neurological
Institute “Carlo Besta”, Milan, Italy. 11University of Utah, Salt Lake City, UT,
USA. 12Greater Glasgow and Clyde NHS Yorkhill Hospital, Glasgow, UK.
13
Birmingham Heartlands Hospital, Birmingham, UK. 14Nationwide Children’s
Hospital, Columbus, OH, USA. 15Ann and Robert H. Lurie Children’s Hospital,
Chicago, IL, USA. 16University of Calgary, Calgary, Canada. 17University of New
Mexico, Albuquerque, NM, USA. 18Boston Children’s Hospital, Boston, MA,
USA. 19Children’s Hospital, Technical University Dresden, Dresden, Germany.
20
University of Essen, Essen, Germany. 21Children’s University Hospital,
Göttingen, Göttingen, Germany. 22University of Torino, Turin, Italy. 23UC Davis
Medical Center, Sacramento, CA, USA. 24University of Messina AOU Policlinico
Gaetano Martino, Messina, Italy. 25University of Kansas Medical Center, Kansas
City, KS, USA. 26Nemours Children’s Hospital, Orlando, FL, USA. 27Penn State
College of Medicine, Hershey, PA, USA. 28Children’s Hospital of Eastern
Ontario, Ottawa, Canada. 29Royal Manchester Children’s Hospital, Manchester,
UK. 30University of Padova, Padua, Italy. 31Vanderbilt Children’s Hospital,
Nashville, TN, USA. 32University of North Carolina School of Medicine, Chapel
Hill, NC, USA. 33Children’s National Medical Center, Washington, DC, USA.
34
Children’s Hospital London Health Sciences Centre, London, Canada.
Received: 6 April 2017 Accepted: 12 April 2018

References
1. International rare disease research consortium. Policies and guidelines. 2013.
http://www.irdirc.org/wp-content/uploads/2017/10/IRDiRC_policies_
24MayApr2013.pdf. Accessed 8 May 2018.
2. International rare disease research consortium. Visions and goals.
http://www.irdirc.org/about-us/vision-goals/. Accessed May 2018.
3. Griggs RC, et al. Clinical research for rare disease: opportunities, challenges,
and solutions. Mol Genet Metab. 2009;96:20–6.
4. Atal I, Trinquart L, Porcher R, Ravaud P. Differential globalization of industryand non-industry-sponsored clinical trials. PLoS One. 2015;10:e0145122.
5. Minisman G, et al. Implementing clinical trials on an international
platform: challenges and perspectives. J Neurol Sci. 2012; https://doi.
org/10.1016/j.jns.2011.10.004.
6. Neaton JD, et al. Regulatory impediments jeopardizing the conduct of
clinical trials in Europe funded by the National Institutes of Health. Clin.
Trials. 2010; https://doi.org/10.1177/1740774510376547.
7. Reith C, et al. Randomized clinical trials–removing unnecessary obstacles.
N Engl J Med. 2013;369:1061–5.
8. Aban IB, et al. The MGTX experience: challenges in planning and
executing an international, multicenter clinical trial. J Neuroimmunol.
2008;201–202:80–4.
9. EURORDIS Rare Diseases Europe. Position Paper. European Reference Networks
for Rare Diseases. 2012. https://www.eurordis.org/sites/default/files/EURORDIS_
Position_paper_on_ERN_May_2012.pdf. Accessed 8 May 2018.
10. Bollyky TJ, Cockburn IM, Berndt E. Bridging the gap: improving clinical
development and the regulatory pathways for health products for
neglected diseases. Clin Trials. 2010;7:719–34.
11. Hartmann M, Hartmann-Vareilles F. The clinical trials directive: how is it
affecting Europe’s noncommercial research? PLoS Clin Trials. 2006;1:e13.
12. Bushby K, Lynn S, Straub V. Collaborating to bring new therapies to the
patient - the TREAT-NMD model. Acta Myologica. 2009;28(1):12–15.
13. Demotes-Mainard J. ECRIN (European Clinical Research Infrastructures
Network), a pan-European infrastructure for clinical research. Bull l’Académie
Natl médecine. 2010;194:1683–94.
14. Becker R, van Dongen GAMS. EATRIS, a vision for translational research in
Europe. J Cardiovasc Transl Res. 2011;4:231–7.

Page 9 of 9

15. Heads of Medicines Agencies. Clinical Trials Facilitation Group. Guidance
document for sponsors for a Voluntary Harmonisation Procedure (VHP) for
the assessment of multinational Clinical Trial Applications. Version 4; 2016.
http://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/
Working_Groups/CTFG/2016_06_CTFG_VHP_guidance_for_sponsor_v4.pdf.
Accessed 8 may 2018.
16. Atzor S, Gokhale S, Doherty M. Will the EU clinical trials regulation support
the innovative industry in bringing new medicines faster to patients?
Pharmaceut Med. 2013;27:75–82.
17. European Parliament and Council of the European Union. Regulation (EU)
No 536/2014. Off J Eur Union. 2014;L:1–76.
18. European Parliament and Council of the European Union. Proposal for a
REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on
clinical trials on medicinal products for human use, and repealing Directive
2001/20/EC, vol. 53; 2012. p. 1689–99.
19. Natelson Love M, Fathallah-Shaykh H. Network for excellence in
neuroscience clinical trials: NeuroNEXT. JAMA Neurol. 2013;70:1227–8.
20. Ullman K. A burst of speed for neurological research: NeuroNEXT
streamlines research processes to encourage collaboration and make rapid
advances. Ann Neurol. 2013;74:A7–8.
21. Department of Health and Human Services. NPRM for federal policy for
the protection of human participants. 2015. https://www.federalregister.
gov/articles/2015/09/08/2015-21756/federal-policy-for-the-protection-ofhuman-subjects. Accessed 8 May 2018.
22. Hudson KL, Collins FS. Bringing the Common Rule into the 21st century. N
Engl J Med. 2015;373:2293–6.
23. Emanuel EJ. Reform of clinical research regulations, finally. N Engl J Med.
2015;373:2296–9.
24. Minisman G, et al. Implementing clinical trials on an international platform:
challenges and perspectives. J Neurol Sci. 2012;313:1–6.
25. Bushby K, Griggs R. 145th ENMC International Workshop: planning for an
international trial of steroid dosage regimes in DMD (FOR DMD), 22-24th
October 2006, Naarden, The Netherlands. Neuromuscul. Disord. 2007;17:423–8.
26. Bushby K, et al. Diagnosis and management of Duchenne muscular dystrophy,
part 1: diagnosis, and pharmacological and psychosocial management. Lancet
Neurol. 2010; https://doi.org/10.1016/S1474-4422(09)70271-6.
27. Bushby K, et al. Diagnosis and management of Duchenne muscular
dystrophy, part 2: implementation of multidisciplinary care. Lancet
Neurol. 2010;9:177–89.
28. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for
Duchenne muscular dystrophy. Cochrane Database of Systematic Reviews.
2008; https://doi.org/10.1002/14651858.CD003725.pub3.
29. Griggs RC, et al. Corticosteroids in Duchenne muscular dystrophy: major
variations in practice. Muscle Nerve. 2013;48:27–31.
30. European Commission. DIRECTIVE 2001/20/EC OF THE EUROPEAN
PARLIAMENT AND OF THE COUNCIL of 4 April 2001 on the approximation
of the laws, regulations and administrative provisions of the Member States
relating to the implementation of good clinical practice in the conduct of
clinical trials on medicinal products for human use. Off J Eur Communities.
2001;L 269:1–15.
31. Gøtzsche PC. Deficiencies in proposed new EU regulation of clinical trials.
BMJ. 2012;345:e8522.
32. Escolar DM, Henricson EK, Pasquali L, Gorni K, Hoffman EP. Collaborative
translational research leading to multicenter clinical trials in Duchenne
muscular dystrophy: the Cooperative International Neuromuscular Research
Group (CINRG). Neuromuscul Disord. 2002;12:S147–54.
33. Gawande A. The checklist manifesto: how to get things right. London:
Profile; 2010.
34. Haynes AB, et al. A surgical safety checklist to reduce morbidity and
mortality in a global population. N Engl J Med. 360:491–9. (209AD)

